A compound according to Formula I: wherein: X is independently CH or N; Y is H or methyl; a is 0 or 1; b is 0 or 1; m is 0, 1 or 2; n is 3; Ring A is (C 3 -C 8)cycloalkenyl, aryl or heterocycle optionally substituted with one to three substituents independently selected from R 1; R 1 is selected from: H, oxo, (C=O) a O b (C 1 -C 10)alkyl, (C=O) a O b -aryl, (C=O) a O b (C 2 -C 10)alkenyl, (C=O) a O b (C 2 -C 10)alkynyl, CO 2 H, halo, OH, O b (C 1 -C 6)fluoroalkyl, (C=O) a NR 5 R 6, CN, (C=O) a O b (C 3 -C 8)cycloalkyl, S m NR 5 R 6, SH, S m -(C 1 -C 10)alkyl and (C=O) a O b -heterocyclyl, said alkyl, aryl, alkenyl, alkynyl, cycloalkyl, and heterocyclyl are optionally substituted with one or more substituents selected from R a; R 2 and R 3 are independently selected from: H, (C=O) a O b C 1 -C 10 alkyl, (C=O) a O b aryl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, (C=O) a O b heterocyclyl, CO 2 H, CN, O b C 1 -C 6 fluoroalkyl, O a (C=O) b NR 5 R 6, CHO, (N=O)R 5 R 6, S m NR 5 R 6, SH, S m -(C 1 -C 10)alkyl, (C=O) a O b C 3 -C 8 cycloalkyl, optionally substituted with one or more substituents selected from R 1; or R 2 and R 3 can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 3-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one or more substituents selected from R 1; R 4 is independently selected from: (C 1 -C 6)alkyl, OH, methoxy, CF 3 and F, said alkyl optionally substituted with OH; R 5 and R 6 are independently selected from: H, (C=O) a O b (C 1 -C 10)alkyl, (C=O) a O b -aryl, (C=O) a O b (C 2 -C 10)alkenyl, (C=O) a O b (C 2 -C 10)alkynyl, CO 2 H, O b (C 1 -C 6)fluoroalkyl, (C=O) a N(R a) 2, CN, (C=O) a O b (C 3 -C 8)cycloalkyl, S m N(R a) 2, SH, S m -(C 1 -C 10)alkyl and (C=O) a O b -heterocyclyl, said alkyl, aryl, alkenyl, alkynyl, cycloalkyl, and heterocyclyl are optionally substituted with one or more substituents selected from R a; R a is independently selected from R b, OH, (C 1 -C 6)alkoxy, halogen, cyclopropyl, CO 2 H, CN, O a (C=O) b (C 1 -C 6)alkyl, oxo, and N(R b) 2; and R b is independently selected from H and (C 1 -C 6)alkyl; or a pharmaceutically acceptable salt or a stereoisomer thereof; for use in treating an inflammatory disease selected from rheumatoid arthritis, inflammatory bowel disease and cancer. X is independently CH or N; Y is H or methyl; a is 0 or 1; b is 0 or 1; m is 0, 1 or 2; n is 3; Ring A is (C 3 -C 8)cycloalkenyl, aryl or heterocycle optionally substituted with one to three substituents independently selected from R 1; R 1 is selected from: H, oxo, (C=O) a O b (C 1 -C 10)alkyl, (C=O) a O b -aryl, (C=O) a O b (C 2 -C 10)alkenyl, (C=O) a O b (C 2 -C 10)alkynyl, CO 2 H, halo, OH, O b (C 1 -C 6)fluoroalkyl, (C=O) a NR 5 R 6, CN, (C=O) a O b (C 3 -C 8)cycloalkyl, S m NR 5 R 6, SH, S m -(C 1 -C 10)alkyl and (C=O) a O b -heterocyclyl, said alkyl, aryl, alkenyl, alkynyl, cycloalkyl, and heterocyclyl are optionally substituted with one or more substituents selected from R a; R 2 and R 3 are independently selected from: H, (C=O) a O b C 1 -C 10 alkyl, (C=O) a O b aryl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, (C=O) a O b heterocyclyl, CO 2 H, CN, O b C 1 -C 6 fluoroalkyl, O a (C=O) b NR 5 R 6, CHO, (N=O)R 5 R 6, S m NR 5 R 6, SH, S m -(C 1 -C 10)alkyl, (C=O) a O b C 3 -C 8 cycloalkyl, optionally substituted with one or more substituents selected from R 1; or R 2 and R 3 can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 3-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one or more substituents selected from R 1; R 4 is independently selected from: (C 1 -C 6)alkyl, OH, methoxy, CF 3 and F, said alkyl optionally substituted with OH; R 5 and R 6 are independently selected from: H, (C=O) a O b (C 1 -C 10)alkyl, (C=O) a O b -aryl, (C=O) a O b (C 2 -C 10)alkenyl, (C=O) a O b (C 2 -C 10)alkynyl, CO 2 H, O b (C 1 -C 6)fluoroalkyl, (C=O) a N(R a) 2, CN, (C=O) a O b (C 3 -C 8)cycloalkyl, S m N(R a) 2, SH, S m -(C 1 -C 10)alkyl and (C=O) a O b -heterocyclyl, said alkyl, aryl, alkenyl, alkynyl, cycloalkyl, and heterocyclyl are optionally substituted with one or more substituents selected from R a; R a is independently selected from R b, OH, (C 1 -C 6)alkoxy, halogen, cyclopropyl, CO 2 H, CN, O a (C=O) b (C 1 -C 6)alkyl, oxo, and N(R b) 2; and R b is independently selected from H and (C 1 -C 6)alkyl; or a pharmaceutically acceptable salt or a stereoisomer thereof; for use in treating an inflammatory disease selected from rheumatoid arthritis, inflammatory bowel disease and cancer.